Dayu Lv

TL;DR: A new version of the UVA/PADOVA Type 1 Diabetes Simulator, which was submitted to FDA in 2013, provides a more reliable framework for in silico trials, for testing glucose sensors and insulin augmented pump prediction methods, and for closed-loop single/dual hormone controller design, testing, and validation.

TL;DR: The new T1D simulator reproduces the intraday glucose variability observed in clinical data, also describing the nocturnal glucose increase, and the simulated insulin profiles reflect real life data, enabling a more realistic framework for in silico testing of advanced diabetes technologies.

TL;DR: Use of the novel adaptive AP in an outpatient, single-arm, uncontrolled multicenter clinical trial lasting 12 weeks yielded significant reductions in HbA1c and hypoglycemia.

TL;DR: A one-time algorithmic adjustment of open-loop settings did not alter glucose control in a relatively short duration outpatient closed-loop study, and the CLC system proved very robust and adaptable, with minimal (<2%) time spent in the hypoglycemic range in either arm.

TL;DR: A CGM/insulin informed advisory system proved to be safe and feasible in a cohort of 24 T1DM subjects and may result in reduced GV and improved protection against hypoglycemia.